Nurix Therapeutics Inc Stock News

SAN FRANCISCO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Gwenn M. Hansen, Ph.D., chief scientific officer of Nurix, will present an update on Nurix's Degrader-Antibody Conjugate (DAC) plat...

Nurix Therapeutics leverages the ubiquitin-proteasome system for targeted protein degradation (TPD) and elevation (TPE) in cancer and autoimmune diseases, with promising early-stage clinical data. Key programs include BTK, IKZF, and CBL-B targets, with notable molecules NX-5948, NX-2127, and NX-1607 showing potential in heavily pretreated B-cell malignancies. Strategic partnerships with Gilead,...

SAN FRANCISCO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D, Ph.D., president and chief executive officer of Nurix, Hans van Houte, chief financial officer of Nurix, and J...

Presented positive clinical data at the European Hematology Association Congress supporting a potential best-in-class profile for NX-5948 for the treatment of CLL

Nurix Therapeutics raised $209m in its IPO in July 2020, focusing on protein degradation in drug development, primarily in the blood cancer space. Protein degradation involves marking proteins for destruction by the proteasome using bifunctional small molecules. Nurix's lead proprietary candidate NX-5948 showed promising results in a Phase 1a clinical study for CLL patients in data released thi...

San Francisco-based Nurix Therapeutics reported robust results in an ongoing treatment against a stubborn form of leukemia.

Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations

Expanded C-level team poised to accelerate development of NX-5948 in B cell malignancies Expanded C-level team poised to accelerate development of NX-5948 in B cell malignancies